Next Article in Journal
Transcriptome and Gene Ontology (GO) Enrichment Analysis Reveals Genes Involved in Biotin Metabolism That Affect l-Lysine Production in Corynebacterium glutamicum
Previous Article in Journal
MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis
Previous Article in Special Issue
Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2016, 17(3), 350; doi:10.3390/ijms17030350

A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection

1
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Kaisei Hospital, Osaka City, Osaka 532-0003, Japan
2
Laboratory of Host Defenses Institute for Advanced Medical Science, Hyogo College of Medicine, Nishinomiya City, Hyogo 668-8501, Japan
3
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Hospital of Japan Community Healthcare Organization, Osaka city, Osaka 553-0003, Japan
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Tatsuo Kanda
Received: 23 December 2015 / Revised: 19 February 2016 / Accepted: 24 February 2016 / Published: 9 March 2016
(This article belongs to the Special Issue Viral Hepatitis Research)
View Full-Text   |   Download PDF [3642 KB, uploaded 9 March 2016]   |  

Abstract

The restoration of innate immune responses has potential as a novel therapeutic strategy for chronic hepatitis C (CHC). We compared the efficacy and safety of induction therapy (IT) with natural interferon-β (n-IFN-β) followed by pegylated-IFN-α/ribavirin (PR) alone (group A, n = 30) and IT with a protease inhibitor (PI) (simeprevir or vaniprevir)/PR (group B, n = 13) in CHC patients with genotype 1b and high viral loads. During IT with nIFN-β, virologic response rates in group A and group B were 10% and 8% (p = 0.6792) at week 4, 30% and 16% (p = 0.6989) at week 12 and 47% and 20% (p = 0.0887) at week 24 respectively. During and after the treatment with PR alone or PI/PR, virologic response rates in groups A and B were 50% and 82% (p = 0.01535) at week 4, 53% and 91% (p = 0.006745) at week 8, 57% and 91% (p = 0.001126) at week 12, 57% and 100% (p < 0.001845) at the end of the treatment and 57% and 80% (p < 0.005166) after treatment cessation. IT with PI/PR linked to the restoration of innate immune response was tolerated well, overcame virological breakthrough, enhanced early virologic responses, and resulted in a sustained virologic response in difficult-to-treat CHC patients. IT with PI/PR is beneficial for treating difficult-to-treat CHC patients. View Full-Text
Keywords: chronic hepatitis C; protease inhibitor; Peg-IFN-α; ribavirin; interferon-β; induction therapy chronic hepatitis C; protease inhibitor; Peg-IFN-α; ribavirin; interferon-β; induction therapy
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kishida, Y.; Imaizumi, N.; Tanimura, H.; Kashiwamura, S.; Kashiwagi, T. A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection. Int. J. Mol. Sci. 2016, 17, 350.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top